D. Western Therapeutics Institute
4576
Needs Well
3992
Daiwa Cycle
5888
Osaka Yuka Industry
4124
Liberta
4935
(FY)Jun 30, 2024 | (Q4)Jun 30, 2024 | (Q3)Mar 31, 2024 | (Q2)Dec 31, 2023 | (Q1)Sep 30, 2023 | (FY)Jun 30, 2023 | (Q4)Jun 30, 2023 | (Q3)Mar 31, 2023 | (Q2)Dec 31, 2022 | (Q1)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 13.98%24.42B | 26.29%6.61B | 7.04%6.06B | 10.90%6.1B | 12.35%5.65B | 14.55%21.42B | 6.51%5.24B | 12.50%5.66B | 16.86%5.5B | 24.18%5.03B |
Cost of revenue | 12.16%13.49B | 10.73%3.51B | 7.33%3.41B | 13.51%3.3B | 17.89%3.27B | 22.97%12.03B | 18.14%3.17B | 27.36%3.17B | 22.26%2.9B | 24.62%2.78B |
Gross profit | 16.31%10.93B | 50.21%3.1B | 6.67%2.66B | 7.97%2.8B | 5.51%2.37B | 5.32%9.4B | -7.49%2.06B | -2.07%2.49B | 11.36%2.59B | 23.63%2.25B |
Operating expense | 11.84%6.83B | 22.48%2.08B | 7.97%1.47B | 12.43%1.59B | 3.53%1.69B | 7.62%6.11B | 5.52%1.69B | -2.80%1.36B | 8.14%1.41B | 20.37%1.63B |
Staff costs | 17.22%4.08B | ---- | ---- | ---- | ---- | 4.66%3.48B | ---- | ---- | ---- | ---- |
Selling and administrative expenses | 14.46%1.04B | ---- | ---- | ---- | ---- | 20.62%907.38M | ---- | ---- | ---- | ---- |
-General and administrative expense | 14.46%1.04B | ---- | ---- | ---- | ---- | 20.62%907.38M | ---- | ---- | ---- | ---- |
Research and development costs | -49.39%190.12M | ---- | ---- | ---- | ---- | -1.78%375.67M | ---- | ---- | ---- | ---- |
Depreciation and amortization | -3.45%259.9M | ---- | ---- | ---- | ---- | 2.16%269.18M | ---- | ---- | ---- | ---- |
-Depreciation | -3.45%259.9M | ---- | ---- | ---- | ---- | 2.16%269.18M | ---- | ---- | ---- | ---- |
Rent and land expenses | -20.17%184.55M | ---- | ---- | ---- | ---- | -3.60%231.18M | ---- | ---- | ---- | ---- |
Other operating expenses | 27.78%1.08B | ---- | ---- | ---- | ---- | 18.59%841.7M | ---- | ---- | ---- | ---- |
Operating profit | 24.62%4.1B | 177.70%1.02B | 5.11%1.19B | 2.63%1.21B | 10.75%681.09M | 1.30%3.29B | -40.96%368.59M | -1.18%1.13B | 15.49%1.18B | 33.21%614.96M |
Net non-operating interest income (expenses) | 78.28%-134K | 63.64%-36K | 114.86%11K | 81.51%-66K | 50.57%-43K | 21.20%-617K | 15.38%-99K | -160.16%-74K | 45.58%-357K | 34.59%-87K |
Non-operating interest income | 13.54%109K | --1K | 61.54%63K | --1K | -22.81%44K | -60.00%96K | --0 | -47.30%39K | --0 | -25.00%57K |
Non-operating interest expense | -49.90%243K | -62.63%37K | -53.98%52K | -48.06%67K | -39.58%87K | -34.64%485K | -38.51%99K | -36.52%113K | -33.51%129K | -31.10%144K |
Total other finance cost | ---- | ---- | ---- | ---- | ---- | -18.86%228K | --0 | --0 | ---- | ---- |
Net investment income | 70.19%9.81M | 455.21%9.69M | -221.09%-2.9M | -9.55%2.51M | 144.21%508K | -1.74%5.77M | -48.33%1.75M | 506.08%2.39M | 104.50%2.78M | -255.90%-1.15M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 80.69%-886K | -294.17%-7.92M | 3,791.27%4.9M | 367.24%3.12M | 35.11%-998K | -150.75%-4.59M | -228.31%-2.01M | -98.54%126K | -119.74%-1.17M | -155.91%-1.54M |
Income from associates and other participating interests | ||||||||||
Special income (charges) | 104.96%9.92M | 105.24%9.92M | 0 | 0 | 0 | -199.99M | -189.16M | 0 | 0 | -10.83M |
Less:Other special charges | -174.12%-9.92M | ---- | ---- | ---- | ---- | --13.38M | --2.55M | --0 | --0 | --10.83M |
Less:Write off | --0 | ---- | ---- | ---- | ---- | --186.61M | ---- | ---- | ---- | ---- |
Other non-operating income (expenses) | 230.60%13.83M | 146.58%4.85M | 1,160.91%10.81M | 46.23%-449K | -632.28%-1.38M | -241.52%-10.59M | -920.57%-10.42M | 185.02%857K | -78.04%-835K | 68.60%-189K |
Income before tax | 34.17%4.13B | 516.73%1.04B | 5.94%1.2B | 3.03%1.21B | 12.98%679.18M | 3.02%3.08B | -60.17%168.65M | 0.24%1.13B | 18.37%1.18B | 36.10%601.17M |
Income tax | 30.04%1.28B | 399.55%163.41M | 9.69%440.51M | 17.92%480.61M | -14.79%196.21M | 4.33%984.85M | -10.07%-54.55M | -4.69%401.58M | 3.80%407.56M | 28.25%230.27M |
Net income | 36.11%2.85B | 292.78%876.67M | 3.87%757.43M | -4.84%733.86M | 30.22%482.97M | 2.42%2.09B | -52.81%223.2M | 3.18%729.21M | 27.85%771.22M | 41.47%370.9M |
Net income continuous operations | 36.11%2.85B | 292.78%876.67M | 3.87%757.43M | -4.84%733.86M | 30.22%482.97M | 2.42%2.09B | -52.81%223.2M | 3.18%729.21M | 27.85%771.22M | 41.47%370.9M |
Noncontrolling interests | 0 | 0 | ||||||||
Net income attributable to the company | 36.11%2.85B | 292.78%876.67M | 3.87%757.43M | -4.84%733.86M | 30.22%482.97M | 2.42%2.09B | -52.81%223.2M | 3.18%729.21M | 27.85%771.22M | 41.47%370.9M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 36.11%2.85B | 292.78%876.67M | 3.87%757.43M | -4.84%733.86M | 30.22%482.97M | 2.42%2.09B | -52.81%223.2M | 3.18%729.21M | 27.85%771.22M | 41.47%370.9M |
Gross dividend payment | ||||||||||
Basic earnings per share | 37.68%76.62 | 300.00%23.72 | 5.27%20.39 | -4.10%19.65 | 30.43%12.86 | 2.35%55.65 | -52.82%5.93 | 3.09%19.37 | 27.74%20.49 | 41.46%9.86 |
Diluted earnings per share | 37.68%76.62 | 300.05%23.72 | 5.27%20.39 | -4.09%19.65 | 30.43%12.86 | 2.35%55.65 | -52.83%5.9293 | 3.12%19.37 | 27.78%20.4878 | 41.46%9.86 |
Dividend per share | 26.67%19 | 26.67%19 | 0 | 0 | 0 | 25.00%15 | 25.00%15 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |